1:19 PM
 | 
Dec 14, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe plaque psoriasis. ECLIPSE is the first head-to-head Phase III trial to compare efficacy between the drugs. Tremfya is a human HuCAL mAb targeting the IL-23 subunit α (IL23P19; IL-23A) and Cosentyx is a human IgG1 mAb targeting IL-17A.

The double-blind, international trial enrolled 1,048 patients to receive 100 mg subcutaneous Tremfya at weeks 0, 4 and 12 followed by every eight-week dosing, or 300 mg subcutaneous Cosentyx at weeks 0, 1, 2, 3 and 4 followed by every four-week dosing. On the primary endpoint, a significantly...

Read the full 584 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >